Tirzepatide is a once-weekly injectable peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It has been studied in randomised clinical trials in adults with type 2 diabetes, in adults with obesity or overweight, and in adults with obstructive sleep apnoea and obesity, with outcomes such as glycated haemoglobin, body weight, sleep-apnoea measures and cardiovascular events. Laboratory studies in cells, isolated islets and mice have been used to examine how the two receptor activities contribute to its effects.
Research overview
Tirzepatide, a dual GIP/GLP-1 receptor agonist, is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. Those approvals are specific to those branded products, dosing and indications. Clinical research into tirzepatide continues in additional populations and combinations.
Mechanism of action
Tirzepatide was designed as a single fatty-acid-modified peptide with agonist activity at both the GIP and GLP-1 receptors. In the original characterisation, it activated both receptor signalling pathways in cell assays, and in mice it improved glucose tolerance through both receptors and reduced body weight and food intake to a greater extent than a GLP-1 receptor agonist [PMID 30473097].
Receptor pharmacology work has described the molecule as 'imbalanced' and 'biased'. Occupancy calculations reported a greater degree of engagement of the GIP receptor than the GLP-1 receptor, and signalling studies reported that tirzepatide mimics native GIP at the GIP receptor but, at the GLP-1 receptor, favours cyclic AMP generation over beta-arrestin recruitment [PMID 32730231].
The relative contribution of the GIP receptor component to the observed effects remains an open research question. In human islets, blocking the GIP receptor was reported to reduce the insulin response to tirzepatide, whereas in mouse islets the insulin response appeared to be mediated mainly through the GLP-1 receptor [PMID 37277609]. A review of the physiology and pharmacology concluded that the GIP receptor contribution is uncertain and proposed alternative hypotheses for the mode of action to be tested in future clinical trials [PMID 37551549].
Adult human evidence
In adults with type 2 diabetes, an open-label 40-week phase 3 trial (SURPASS-2, 1879 participants) compared tirzepatide with the GLP-1 receptor agonist semaglutide. Reductions in glycated haemoglobin and body weight were reported to be greater in all tirzepatide arms than with semaglutide. Gastrointestinal events (nausea, diarrhoea, vomiting) were the most common adverse events in both groups, and serious adverse events were reported in 5 to 7% of tirzepatide-treated participants and 3% of semaglutide-treated participants [PMID 34170647].
In adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an open-label 52-week trial against insulin glargine (SURPASS-4, 2002 randomised participants) reported greater HbA1c reductions with tirzepatide and a lower proportion of participants with hypoglycaemia. Adjudicated major adverse cardiovascular events were reported not to be increased relative to glargine [PMID 34672967]. A later double-blind outcomes trial in 13,299 randomised adults with type 2 diabetes and atherosclerotic cardiovascular disease (SURPASS-CVOT) compared tirzepatide with dulaglutide: the primary composite end point met the pre-specified non-inferiority criterion, while superiority was not demonstrated (hazard ratio 0.92; 95.3% CI 0.83 to 1.01), and more gastrointestinal adverse events were observed with tirzepatide [PMID 41406444].
In adults with obesity or overweight without diabetes, the 72-week double-blind SURMOUNT-1 trial (2539 participants) reported substantial mean body-weight reductions in all tirzepatide arms compared with placebo; the most common adverse events were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation, and adverse events led to discontinuation in 2.6% of placebo participants and 4.3% to 7.1% of participants in the tirzepatide arms [PMID 35658024]. In a randomised-withdrawal design (SURMOUNT-4, 670 randomised participants after a 36-week lead-in), participants switched to placebo were reported to regain a substantial part of the lost weight, whereas those continuing tirzepatide maintained or added to the reduction [PMID 38078870]. An open-label phase 3b head-to-head trial in 751 adults with obesity but without diabetes reported greater weight and waist-circumference reductions at 72 weeks with tirzepatide than with semaglutide (SURMOUNT-5) [PMID 40353578].
In two phase 3 trials in adults with moderate-to-severe obstructive sleep apnoea and obesity (SURMOUNT-OSA), tirzepatide was reported to reduce the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure compared with placebo over 52 weeks; gastrointestinal events were the most frequently reported adverse events [PMID 38912654].
Preclinical evidence
Preclinical work consists mainly of cell-signalling studies, isolated islets and mouse models. These are not human efficacy data. In obese mice, tirzepatide improved insulin sensitivity to a greater extent than GLP-1 receptor agonism; in Glp-1r-null mice it still improved insulin sensitivity by enhancing glucose disposal in white adipose tissue, and a long-acting GIP receptor agonist produced a similar effect, which the authors interpreted as a GIP receptor contribution independent of weight loss [PMID 34003802].
Studies of islets and receptors reported species differences: in mouse islets tirzepatide stimulated insulin secretion predominantly through the GLP-1 receptor because of reduced potency at the mouse GIP receptor, whereas in human islets both incretin receptors contributed, and glucagon and somatostatin secretion were also increased [PMID 37277609]. Cell-based work described biased signalling at the GLP-1 receptor and greater GIP receptor engagement [PMID 32730231]. The original discovery paper reported in vitro and mouse data, together with an early phase 1 programme, and is cited here for the mouse findings [PMID 30473097].
Evidence limitations
Most trials reviewed lasted roughly 40 weeks to two years, with one large cardiovascular outcomes trial in type 2 diabetes whose duration is not stated in the abstract; effects and safety over longer periods are less well characterised.
Trials were conducted in defined adult populations (type 2 diabetes, obesity or overweight, or obstructive sleep apnoea with obesity) under clinical supervision; results may not apply to other groups or settings, and the abstracts reviewed do not report findings for children or adolescents.
Gastrointestinal adverse events were the most commonly reported in every trial reviewed, and treatment discontinuation due to adverse events occurred in a minority of participants; the labelling for the approved product also carries a boxed warning on thyroid C-cell tumours observed in rats, with human relevance not determined.
In the SURMOUNT-4 randomised-withdrawal trial, participants who stopped tirzepatide regained a substantial amount of weight, so findings relate to the period of treatment rather than to lasting effects after stopping.
The mechanistic contribution of GIP receptor agonism in humans is not settled; species differences (mouse vs human islets) mean mouse findings may not translate directly.
Several key trials (SURPASS-2, SURPASS-4, SURMOUNT-5, and the lead-in of SURMOUNT-4) were open-label, and all trials listed were funded by the sponsor, Eli Lilly and Company.
Trial results relate to the pharmaceutical product, dose regimen and clinical supervision used in those studies; they cannot be applied to research-grade material of unverified identity, purity or formulation.
Research and regulatory status
Tirzepatide is a regulated pharmaceutical. The site's reviewed statement (last reviewed 2026-09-22) records FDA approval as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity. For this dossier the Zepbound label (revised 03/2024) was fetched from the FDA's Drugs@FDA site and confirms the chronic weight-management indication (initial US approval 2022); the Mounjaro and sleep-apnoea indications and the current regulatory record were not re-checked. Approvals apply only to the specific pharmaceutical products, doses and indications, not to research-grade material.
Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021
Design
Open-label, 40-week, randomised phase 3 trial (SURPASS-2) with tirzepatide dose arms versus semaglutide
Participants / model
Adults with type 2 diabetes (mean baseline HbA1c 8.28%, mean age 56.6 years)
Sample size
1879 patients
Principal findings
Change in glycated haemoglobin from baseline to 40 weeks was greater in all tirzepatide arms than with semaglutide, and body-weight reductions were also greater. The most common adverse events were gastrointestinal; serious adverse events were reported in 5 to 7% of tirzepatide-treated and 3% of semaglutide-treated participants.
Limitations
Open-label design with a 40-week duration; sponsor-funded, and conducted only in adults with type 2 diabetes.
Del Prato S, Kahn SE, Pavo I, et al. · Lancet (London, England) · 2021
Design
Open-label, parallel-group, randomised phase 3 trial with tirzepatide arms versus insulin glargine
Participants / model
Adults with type 2 diabetes, inadequately controlled on oral glucose-lowering medicines, with established cardiovascular disease or high cardiovascular risk
Sample size
2002 randomised (1995 in the modified intention-to-treat population)
Principal findings
HbA1c reductions at 52 weeks were greater with tirzepatide than glargine, and hypoglycaemia was reported in a smaller percentage of tirzepatide-treated participants. Nausea, diarrhoea, decreased appetite and vomiting were more frequent with tirzepatide, and adjudicated MACE-4 events were not increased compared with glargine (hazard ratio 0.74, 95% CI 0.51 to 1.08).
Limitations
Open-label; the cardiovascular analysis was a safety assessment with few adjudicated events (109), so it was not designed to show cardiovascular benefit.
Adults with type 2 diabetes and atherosclerotic cardiovascular disease
Sample size
13,299 randomised; 6586 (tirzepatide) and 6579 (dulaglutide) in the modified intention-to-treat population
Principal findings
The composite of cardiovascular death, myocardial infarction or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group (hazard ratio 0.92; 95.3% CI 0.83 to 1.01), meeting non-inferiority; superiority was not shown (P = 0.09). Adverse-event incidence appeared similar, with more gastrointestinal events in the tirzepatide group.
Limitations
The comparator was an active GLP-1 receptor agonist rather than placebo, and the population was restricted to adults with type 2 diabetes and established cardiovascular disease.
Adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes
Sample size
2539 adults
Principal findings
Mean percentage change in body weight at week 72 was substantially greater in all tirzepatide arms than with placebo (-3.1%), and the share of participants reaching at least 5% weight reduction was higher. The most common adverse events were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation; adverse events caused discontinuation in 2.6% of placebo participants and in 4.3% to 7.1% of tirzepatide participants.
Limitations
Participants without diabetes only and 72-week duration; sponsor-funded.
Aronne LJ, Sattar N, Horn DB, et al. · JAMA · 2024
Design
Phase 3 randomised-withdrawal trial: 36-week open-label tirzepatide lead-in, then 52-week double-blind placebo-controlled period
Participants / model
Adults with a BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes
Sample size
783 in the lead-in; 670 randomised
Principal findings
From week 36 to week 88 the mean weight change was -5.5% with continued tirzepatide versus +14.0% with placebo. Participants switched to placebo regained a substantial amount of lost weight. Adverse events were mostly mild-to-moderate gastrointestinal events, more common with tirzepatide.
Limitations
Only participants who completed the lead-in period were randomised, so results do not represent everyone who started treatment; follow-up ended at 88 weeks.
Mean percent change in weight at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide (P<0.001), with greater waist-circumference reduction in the tirzepatide group. The most common adverse events in both groups were gastrointestinal, mostly mild to moderate and occurring mainly during dose escalation.
Limitations
Open-label design; both agents were given at the maximum tolerated dose, and the study was sponsor-funded.
Malhotra A, Grunstein RR, Fietze I, et al. · The New England journal of medicine · 2024
Design
Two double-blind, randomised, placebo-controlled phase 3 trials (SURMOUNT-OSA), 52 weeks
Participants / model
Adults with moderate-to-severe obstructive sleep apnoea and obesity, not on positive airway pressure (trial 1) or on it (trial 2)
Sample size
not stated in the abstract
Principal findings
Change in the apnoea-hypopnoea index at week 52 was larger with tirzepatide than with placebo in both trials, with improvements also reported in body weight, hypoxic burden, hsCRP and systolic blood pressure. The most frequently reported adverse events were gastrointestinal and mostly mild to moderate.
Limitations
Limited to adults with both obstructive sleep apnoea and obesity over 52 weeks; sponsor-funded.
Willard FS, Douros JD, Gabe MB, et al. · JCI insight · 2020
Design
In vitro pharmacology and receptor-occupancy analysis, including primary islet experiments
Participants / model
Cell-based receptor signalling assays and primary islets (species not stated in the abstract)
Sample size
not stated in the abstract
Principal findings
Occupancy analysis reported greater engagement of the GIP receptor than the GLP-1 receptor. Tirzepatide mimicked native GIP at the GIP receptor but showed bias at the GLP-1 receptor towards cAMP generation over beta-arrestin recruitment, with weaker receptor internalisation than native GLP-1.
Limitations
Cell and islet experiments cannot show what happens in people; the occupancy calculation depends on modelling assumptions.
Samms RJ, Christe ME, Collins KA, et al. · The Journal of clinical investigation · 2021
Design
Mouse experiments comparing wild-type and Glp-1r-null mice, with a long-acting GIPR agonist
Participants / model
Obese mice (wild-type and Glp-1r-null)
Sample size
not stated in the abstract
Principal findings
Tirzepatide improved insulin sensitivity in obese mice to a greater extent than GLP-1 receptor agonism. In Glp-1r-null mice it still improved insulin sensitivity by enhancing glucose disposal in white adipose tissue, which the authors attributed to GIP receptor agonism.
Limitations
Findings are from mice, and the authors note the mechanism is not fully understood; translation to humans is not established.
El K, Douros JD, Willard FS, et al. · Nature metabolism · 2023
Design
Ex vivo islet hormone-secretion experiments in mouse and human islets
Participants / model
Mouse islets and human islets
Sample size
not stated in the abstract
Principal findings
In mouse islets tirzepatide stimulated insulin secretion predominantly through the GLP-1 receptor, owing to reduced potency at the mouse GIP receptor. In human islets, antagonising the GIP receptor consistently decreased the insulin response, and glucagon and somatostatin secretion were enhanced.
Limitations
Isolated islets lack whole-body physiology, and the abstract does not give donor or sample numbers.
Gasbjerg LS, Rosenkilde MM, Meier JJ, et al. · Diabetes, obesity & metabolism · 2023
Design
Narrative review of incretin physiology, molecular pharmacology, and preclinical and clinical data on tirzepatide
Participants / model
Published literature on GLP-1 and GIP receptor biology and tirzepatide
Sample size
not applicable (review)
Principal findings
The authors concluded that the contribution of GIP receptor activation to tirzepatide's effects is uncertain and that tirzepatide does not appear to have a classical co-activating mode of action in humans. They described a biased GLP-1 receptor activation profile and GIP receptor downregulation in vitro, and proposed three hypotheses for future clinical trials.
Limitations
A narrative review published in 2023, so it predates later trials; it presents hypotheses rather than settled mechanisms.
*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.